Compare Kingsoft Cloud Holdings Limited (KC) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kingsoft Cloud Holdings Limited vs Sanofi SA — how do they compare? Kingsoft Cloud Holdings Limited trades at $9.26 (market cap $2.71B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 35.1× Kingsoft Cloud Holdings Limited's market cap, and Sanofi SA pays a 6.01% dividend while Kingsoft Cloud Holdings Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kingsoft Cloud Holdings Limited for 12 Days and Sanofi SA for 94 Days on average.
| KC | SNY | |
|---|---|---|
Market Cap | $2.71B | $95.18B |
Volume | 1,993,765 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $18.21 | $52.34 |
52-Week Low | $8.58 | $39.51 |
Typical Hold Time | 12 Days | 94 Days |
Enterprise Value | $3.03B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kingsoft Cloud (KC) trades at $9.26, up 0.27% with bearish technical signals but strong analyst support. The company shows improving fundamentals with Q2 2026 revenue growth of 30.8% year-over-year and three consecutive earnings beats. While still reporting net losses, gross margins improved significantly and AI cloud services are emerging as a key growth driver, with billings surging 82% year-over-year.
KC presents a compelling turnaround story with 70% analyst buy ratings and 60% upside potential, though risks include persistent losses, competitive pressures, and technical weakness. The AI cloud partnership with Xiaomi positions the stock for growth, but investors should weigh the fundamental improvements against the current bearish technical setup.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kingsoft Cloud Holdings Limited
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
